Experienced in Vaginal Cancer

Dr. Ammar Chaudhry

Neuroradiology
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 
Experienced in Vaginal Cancer
City Of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, 
Duarte, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Ammar Chaudhry is a Neuroradiologist in Duarte, California. Dr. Chaudhry is rated as an Experienced provider by MediFind in the treatment of Vaginal Cancer. His top areas of expertise are ALK-Positive Non-Small Cell Lung Cancer, Mantle Cell Lymphoma (MCL), Lung Nodules, and Meningioma.

His clinical research consists of co-authoring 46 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article in the study of Vaginal Cancer.

Graduate Institution
University Of South Florida College Of Medicine
Specialties
Neuroradiology
Licenses
Diagnostic Radiology in MD
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO

Locations

City of Hope's Helford Clinical Research Hospital
1500 Duarte Rd, Duarte, CA 91010
Other Locations
Office
300 Westage Business Ctr Dr Ste 280, Fishkill, NY 12524

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
A Phase II, Open Label, Multi-Dose Study of ⁸⁹Zr-Df-IAB22M2C (CD8 PET Tracer) for Positron Emission Tomography (PET/CT) in Patients With Selected Advanced or Metastatic Solid Malignancies Who Are Scheduled to Receive Standard-of-Care Immunotherapy Only, As Single Agent or in Combination
Enrollment Status: Completed
Publish Date: July 09, 2024
Intervention Type: Drug
Study Drug: 89Zr-Df-IAB22M2C
Study Phase: Phase 2
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
A Confirmatory, Prospective, Open-label, Multi-centre Phase 3 Study to Evaluate Diagnostic Performance of Zirconium-labelled Girentuximab to Non-invasively Detect ccRCC by PET/CT Imaging in Patients With Indeterminate Renal Masses
Enrollment Status: Completed
Publish Date: May 17, 2024
Intervention Type: Diagnostic test
Study Phase: Phase 3
A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer
A Phase I Study of 68GA-PSMA-11 PET Imaging for Biochemically Recurrent Prostate Cancer
Enrollment Status: Completed
Publish Date: June 15, 2023
Intervention Type: Procedure, Drug
Study Drug: Ga-68 PSMA-11
Study Phase: Phase 1
A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1
A Phase I Study of 64Cu Pembrolizumab PET Imaging for In Vivo Expression of PD1
Enrollment Status: Withdrawn
Publish Date: June 09, 2022
Intervention Type: Radiation, Procedure, Biological
Study Phase: Phase 1
View 3 Less Clinical Trials

46 Total Publications

Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Osimertinib after definitive chemoradiotherapy in unresectable stage III epidermal growth factor receptor-mutated non-small-cell lung cancer: analyses of central nervous system efficacy and distant progression from the phase III LAURA study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: July 05, 2024
Similar Doctors
Distinguished in Vaginal Cancer
Dr. Eric Peters
Neuroradiology
Distinguished in Vaginal Cancer
Dr. Eric Peters
Neuroradiology

Loma Linda Univ Anesthesiology Medical Group Inc

11234 Anderson St, 
Loma Linda, CA 
 (42.6 miles away)
909-558-7814
Languages Spoken:
English
See accepted insurances

Eric Peters is a Neuroradiologist in Loma Linda, California. Dr. Peters is rated as a Distinguished provider by MediFind in the treatment of Vaginal Cancer. His top areas of expertise are X-Linked Intellectual Disability, Siderius Type, Mohr-Tranebjaerg Syndrome, Aicardi-Goutieres Syndrome, and PEHO Syndrome.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chaudhry's expertise for a condition
ConditionClose
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile